Injections will not be g iven into extremities that have had radical lymph node dissec tions. The same extremity wil l be used for each cycle of the peptide loaded dendritic cell vaccine administration. xCells for IV administration (0.5x107to 4.0x107cells) will be infused over 20 to 30 minutes, or as clinically determin ed by an investigator for pati ent safety, via non-filtered tubing, gently agitating the bag during infusion to prevent cel l clumping. See Appendix 1 for cell infusion instructions. xVital signs will be monitore d hourly (±15 minutes) for two hour s. The post- administration monitoring peri od may be adjusted by the PI. xAll patients will recei ve their peptide pulsed dendritic cell v accines in the NIH Clinical Center. The first thr ee patients will recei ve their Day 0 SQ in jection and IV infusion on the In-Patient Care Unit, and then will receive their subsequent SQ injections and IV infusions (days 14, 28, and 42) as out patient procedures in the 3 SE-S Day Hospital. All patients enrolled after the first three patients will receive t heir full course of SQ injections and IV infusions (days 0, 14, 28, and 42) as outpatient procedur es in the 3SE-S Day Hospital. This schedule may be a djusted by the PI as clinically appropriate. ON-STUDY EVALUATION 3.3.1 Within 7 Days Prior to the 1stVaccination (Day 0) xRepeat all screening procedures from Section 2.2.3 if not completed within 7 days prior to the 1stvaccination (Day 0). 3.3.2 Within 2 Days Prior to the 1stVaccination (Day 0) xLymphocyte phenotyping (TBNK) xReview of baseline symptoms xResearch samples as described in Section 5 3.3.3 Within 2 Days Prior to Each Subsequent Vaccination (Days 14, 28, and 42 (± 5 days)) xPhysical examination, including ECOG xVital signs xCBC w/differential Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 19xAcute Care Panel (sodium, potassium, chloride, bicarbonate, cre atinine, glucose, BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, direct bilirubin), Mineral Panel (albumin, calcium, magnesium, phosphorus), Uric Acid, Cre atinine Kinase, Lactate Dehydrogenase, Total Protein xȕ-HCG pregnancy test (serum or urine) on all females of child-bear ing potential xToxicity assessment, including a review of systems xResearch samples as described in Section 5 3.3.4 After Each Vaccination xVital signs will be monitored hour ly (± 15 minutes) for two hours . The post- administration monitoring peri od may be adjusted by the PI. POST-TREATMENT EVALUATION (FOLLOW -UP) 3.4.1 1stFollow-up Evaluation (Day 56 ± 5 days) All patients will return to the NIH Clinical Center for their f irst follow-up evaluation on day 56 (±5 days), which is approximately 2 weeks from the 4thvaccination. At the first follow-up evalu ation, patients will undergo: xPhysical examination, including ECOG xVital signs xCBC w/differential xAcute Care Panel (sodium, potassium, chloride, bicarbonate, cre atinine, glucose, BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, direct bilirubin), Mineral Panel (albumin, calcium, magnesium, phosphorus), Uric Acid, Cre atinine Kinase, Lactate Dehydrogenase, Total Protein xLymphocyte phenotyping (TBNK) xȕ-HCG pregnancy test (serum or urine) on all females of child-bear ing potential xToxicity assessment, including a review of systems xResearch samples as described in Section 5 xImaging studies as performed at baseline to determine tumor resp onse. If clinically indicated, other scans or x-rays may be performed, e.g., brain MRI, bone scan.